Comparative Pharmacology
Head-to-head clinical analysis: EPYSQLI versus LASTACAFT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPYSQLI versus LASTACAFT.
EPYSQLI vs LASTACAFT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Elagolix is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively inhibits GnRH binding, resulting in suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, thereby reducing ovarian sex hormone production.
Selective histamine H1 receptor antagonist; inhibits mast cell degranulation and reduces release of inflammatory mediators.
10 mg orally once daily.
1 drop in each affected eye twice daily (approximately every 8 hours)
None Documented
None Documented
Terminal elimination half-life 12-18 hours (mean 15 h) in adults; requires dose adjustment in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 2 hours; clinically, dosing is twice daily.
Primarily renal excretion (70-80% unchanged), with 10-15% fecal elimination via biliary secretion.
Renal: approximately 70% as unchanged drug; fecal: approximately 30% as metabolites.
Category C
Category C
Ophthalmic Antihistamine
Ophthalmic Antihistamine